Brief: EQRx Announces Two Lancet Oncology Publications Of Phase 3 Results Of Sugemalimab In Stage III And IV Non-Small Cell Lung Cancer
18/01/2022 13:28
Jan 18 (Reuters) - EQRx Inc EQRX.O :
* EQRX ANNOUNCES TWO LANCET ONCOLOGY PUBLICATIONS OF
POSITIVE
PHASE 3 RESULTS OF SUGEMALIMAB IN STAGE III AND STAGE IV
NON-SMALL CELL LUNG CANCER
* EQRX INC - DATA REINFORCE POTENTIAL OF SUGEMALIMAB FOR
TREATMENT
OF THIS BROAD RANGE OF PATIENTS WITH NSCLC
* EQRX-RESULTS FROM PHASE 3 GEMSTONE-301 STUDY SHOW
SUGEMALIMAB
IMPROVES PFS IN PATIENTS WITH STAGE III NSCLC POST
SEQUENTIAL/CONCURRENT CHEMORADIOTHERAPY
Source text for Eikon: ID:nGNXb0J0rl
Further company coverage: EQRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on EQRx
See all newsBrief: Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Revolution Medicines Stockholders Vote "FOR" Proposed Acquisition Of EQRx, Inc
Brief: Revolution Medicines Inc Says Will Acquire EQRx In An All-Stock Transaction
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: EQRx posts Q1 EPS USD -0.17
Brief: EQRx Says Jami Rubin Will Step Down As Chief Financial Officer